+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Biology of RANK, RANKL, and osteoprotegerin

Biology of RANK, RANKL, and osteoprotegerin

Arthritis Research & Therapy 9 Suppl 1: S1-S1

The discovery of the receptor activator of nuclear factor-kappaB ligand (RANKL)/RANK/osteoprotegerin (OPG) system and its role in the regulation of bone resorption exemplifies how both serendipity and a logic-based approach can identify factors that regulate cell function. Before this discovery in the mid to late 1990s, it had long been recognized that osteoclast formation was regulated by factors expressed by osteoblast/stromal cells, but it had not been anticipated that members of the tumor necrosis factor superfamily of ligands and receptors would be involved or that the factors involved would have extensive functions beyond bone remodeling. RANKL/RANK signaling regulates the formation of multinucleated osteoclasts from their precursors as well as their activation and survival in normal bone remodeling and in a variety of pathologic conditions. OPG protects the skeleton from excessive bone resorption by binding to RANKL and preventing it from binding to its receptor, RANK. Thus, RANKL/OPG ratio is an important determinant of bone mass and skeletal integrity. Genetic studies in mice indicate that RANKL/RANK signaling is also required for lymph node formation and mammary gland lactational hyperplasia, and that OPG also protects arteries from medial calcification. Thus, these tumor necrosis factor superfamily members have important functions outside bone. Although our understanding of the mechanisms whereby they regulate osteoclast formation has advanced rapidly during the past 10 years, many questions remain about their roles in health and disease. Here we review our current understanding of the role of the RANKL/RANK/OPG system in bone and other tissues.

(PDF emailed within 0-6 h: $19.90)

Accession: 051812320

Download citation: RISBibTeXText

PMID: 17634140

DOI: 10.1186/ar2165

Related references

RANK, RANKL and osteoprotegerin in bone biology and disease. Current Reviews in Musculoskeletal Medicine 2(1): 56-64, 2009

Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 14(5): 913-918, 2007

Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Research 33(1): 199-206, 2013

Osteoprotegerin, RANK, RANKL. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 145(2): 61-64, 2002

Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). Annales D'endocrinologie 67(2): 139-141, 2006

Comparison of the rank, RANKL and osteoprotegerin expression in the osteoarthritis. 2007

RANK, RANKL and osteoprotegerin in arthritic bone loss. Brazilian Journal of Medical and Biological Research 38(2): 161-170, 2005

RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cellular and Molecular Life Sciences 64(18): 2334-2350, 2007

Expressions of RANK, RANKL, and osteoprotegerin in male rats at different ages. Nan Fang Yi Ke Da Xue Xue Bao 31(9): 1539-1542, 2014

Osteoprotegerin activates osteosarcoma cells that co-express RANK and RANKL. Experimental Cell Research 338(1): 32-38, 2015

The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Journal of Endocrinological Investigation 32(4 Suppl): 6-9, 2010

Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease. World Journal of Surgery 35(9): 1984-1992, 2011

The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease. Current Medicinal Chemistry 18(31): 4813-4819, 2012

Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects. Ginekologia Polska 74(4): 323-331, 2003

In situ expression of RANKL, RANK, osteoprotegerin and cytokines in osteoclasts of rat periodontal tissue. Journal of Periodontal Research 39(1): 42-49, 2003